HER2-positive Breast Cancer
Conditions
Keywords
HER2-positive breast cancer with residual invasive cancer after neoadjuvant therapy
Brief summary
This trial is a registered phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-M07D1 in the adjuvant treatment of HER2-positive breast cancer with residual invasive cancer after neoadjuvant therapy.
Interventions
DRUGBL-M07D1
Administration by intravenous infusion for a cycle of 3 weeks.
DRUGT-DM1
Administration by intravenous infusion for a cycle of 3 weeks.
Sponsors
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Sign the informed consent form voluntarily and follow the protocol requirements; 2. Women aged ≥18 years and ≤75 years at the time of written informed consent; 3. Expected survival time ≥6 months; 4. Patients with histologically confirmed HER2-positive invasive breast cancer; 5. Before neoadjuvant therapy, the clinical TNM staging was T1-4, N0-3, M0 (excluding T1N0) based on the 8th edition of the American Joint Committee on Cancer (AJCC) staging system; 6. The presence of residual invasive cancer confirmed by postoperative pathological examination must meet one of the conditions specified in the protocol; 7. Previous neoadjuvant therapy should meet the prescribed treatment conditions; 8. Had received radical mastectomy; 9. Determine hormone receptor (HR) status; 10. The interval between radical surgery and randomization was at least 3 weeks and at most 12 weeks; 11. ECOG score 0 or 1; 12. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0; 13. No blood transfusion within 14 days before the first use of the study drug and no use of colony-stimulating factors were allowed; 14. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, serum pregnancy must be negative, and the patient must not be lactating; All enrolled patients should use adequate and highly effective contraception during the entire treatment cycle and for 7 months after the end of treatment.
Exclusion criteria
1. A diagnosis of stage IV metastatic breast cancer was made; 2. Bilateral breast cancer; 3. Any previous history of breast cancer (unilateral or contralateral) except for lobular carcinoma in situ (LCIS); 4. Evidence of clinically significant residual disease or recurrent or metastatic disease after neoadjuvant therapy and surgery; 5. Other primary malignancies diagnosed within 5 years before the first dose; 6. Received previous HER2-ADC, immunotherapy, or other antitumor biological therapy; 7. Subjects are participating in other clinical studies and receiving anti-tumor treatment; 8. Prior treatment with anthracyclines, doxorubicin equivalent cumulative dose \> 240 mg/m2; Cumulative dose of epirubicin or liposomal doxorubicin hydrochloride \> 480 mg/m2; 9. History of severe cardiovascular or cerebrovascular disease within six months before screening; 10. QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia; 11. Poorly controlled hypertension (systolic blood pressure \> 150 mmHg or diastolic blood pressure \> 100 mmHg); 12. Complicated with pulmonary diseases leading to severe impairment of lung function; 13. A history of ILD/interstitial pneumonia requiring steroid therapy, current ILD/interstitial pneumonia, or suspected such disease during screening; CTCAE v5.0 was used to define grade ≥3 pulmonary disease and grade ≥2 radiation pneumonitis; 14. Human immunodeficiency virus antibody (HIVAb) positive, active hepatitis B virus infection, liver cirrhosis, or hepatitis C virus infection; 15. Had a serious infection within 4 weeks before the first dose of study drug; There was active pulmonary inflammation at the time of screening; 16. Were receiving \> within 2 weeks before the first dose; 10mg/d prednisone systemic corticosteroids or equivalent anti-inflammatory active drugs or any form of immunosuppressive therapy; 17. Patients with a history of severe allergy to recombinant humanized antibodies or to any of the excipents of BL-M07D1; 18. Known hypersensitivity or delayed hypersensitivity to certain components of T-DM1 or similar drugs, or known contraindications to T-DM1; 19. Had a history of autologous or allogeneic stem cell transplantation or organ transplantation; 20. Have a severe neurological or psychiatric illness; 21. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent; 22. Intestinal obstruction, Crohn's disease, ulcerative colitis or chronic diarrhea; 23. Subjects scheduled to receive live vaccine or within 28 days before the first dose; 24. Patients with other serious physical and laboratory abnormalities or poor adherence that may increase the risk of participating in the study, or interfere with the results of the study, and patients who were deemed by the investigators to be unsuitable for participation in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Invasive Disease-free Survival (IDFS) | Up to approximately 77 months | IDFS refers to the absence of invasive cancer recurrence after breast cancer treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease-free Survival(DFS) | Up to approximately 77 months | DFS is defined as the time from random occurrence of a tumor to recurrence. |
| Distant Recurrence-free Interval (DRFI) | Up to approximately 77 months | DRFI is defined as the interval from the date of randomization to the first occurrence of distant recurrence of breast cancer or death due to breast cancer. |
| Overall Survival (OS) | Up to approximately 77 months | Overall survival (OS) is defined as the time between the subject's randomization date and subject's death. |
| Treatment Emergent Adverse Event (TEAE) | Up to approximately 77 months | TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-M07D1. The type, frequency and severity of TEAE will be evaluated during the treatment of BL-M07D1. |
Countries
China
Contacts
CONTACTSa Xiao, PHD
Outcome results
None listed